Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neovascularization Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPHA3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPHA3 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View EPHA3 Products |
| Gene Delivery | EPHA3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based assays. |
View EPHA3 Products |
| Benchmark Ab | Anti-EPHA3 Recombinant Antibody (Ifabotuzumab Biosimilar) Recombinant positive control for binding and functional assays. |
View EPHA3 Products |
| Validator | EPHA3 siRNA Set For target knockdown and specificity validation. |
View EPHA3 Products |
| Related Target A | EPHA2 Homologous counter-screening target to ensure drug specificity and avoid off-target toxicity. |
View EPHA2 Products |
| Related Target B | EFNA5 Natural ligand of EPHA3; essential for ligand-competition and receptor-activation assays. |
View EFNA5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Cross-Reactivity | Highly purified homologous proteins (EPHA2, EPHA4) available for rigorous counter-screening panels. |
| Conformational Epitope Preservation | HEK293 mammalian expression host ensures native post-translational glycosylation and proper folding of the ECD. |
| Lack of Standard Reference Controls | Sequence-verified clinical benchmark antibody (Ifabotuzumab biosimilar) available for assay calibration. |
| False Positive Knockdown Verification | Sequence-verified siRNA sets provided to confirm target-specific phenotypic changes. |
Live EPHA3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPHA3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and multi-specific cell engagers. As first-generation naked antibodies (such as Ifabotuzumab) demonstrate clinical proof of concept in hematological malignancies and solid tumors, the next wave of R&D is targeting EPHA3's rapid internalization kinetics and tumor-microenvironment-restricted expression to deliver highly cytotoxic payloads while sparing healthy tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Academic & Biopharma Consortia | Glioblastoma, Solid Tumors | Internalization Assay (Requires high-purity, native glycosylated ECD-Fc) |
| Monoclonal Antibodies (mAbs) | Humanigen (Ifabotuzumab/KB004) | AML, Myelofibrosis, Glioma | ADCC / CDC Assays (Requires sequence-verified benchmark antibody controls) |
| Cell Therapies (CAR-T) | Translational Research Institutes | Glioblastoma, Brain Tumors | Target Specificity Screening (Requires stable cell line generation via Lentivirus) |